IRVING, Texas--(BUSINESS WIRE)--A research abstract authored by pathologists at Inform Diagnostics has been awarded “Outstanding Abstract” in the 2018 Therapeutic Drug Management and Toxicology Division Abstract Competition conducted by the American Association for Clinical Chemistry (AACC).
Titled “Therapeutic Drug Monitoring of Monoclonal Antibody in Inflammatory Bowel Disease: Laboratory Evidence to Predict Patient Responses,” the abstract describes a study of 18,837 sera samples collected from adult and pediatric IBD patients receiving monoclonal antibody (mAb) biologic drug treatments that were analyzed using Inform Diagnostics’ assay, which employs an ELISA-based method to measure concentrations of both the drug and patient immunity to the drug (anti-drug antibodies). This study provides laboratory evidence to predict patient response and guide treatment for IBD patients. The authors are Yun Wang, PhD, Kevin Turner, DO, Ahmed Bedeir, MD, Parag Patel, DO, and James Gulizia, MD, PhD.
The Outstanding Abstract award was presented at the AACC Therapeutic Drug Management and Toxicology Division Annual Meeting on Monday, July 30.
About Inform Diagnostics
Inform Diagnostics is the largest independent anatomic pathology lab in the United States, chosen by clinicians every day as a vital provider for their patients’ care. Headquartered in Irving, Texas, the organization was founded in 1996 and previously known as Miraca Life Sciences since 2012. Inform Diagnostics’ premier medical laboratories focus on GI pathology, dermatopathology, hematopathology, urologic pathology, and breast pathology. Each Inform Diagnostics pathologist is a fellowship-trained subspecialist. Learn more online about Inform Diagnostics’ extraordinary quality and service.